Evotec (NASDAQ:EVO – Get Free Report) and InterCure (NASDAQ:INCR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
Profitability
This table compares Evotec and InterCure’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Evotec | N/A | N/A | N/A |
InterCure | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of current recommendations for Evotec and InterCure, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Evotec | 0 | 0 | 3 | 0 | 3.00 |
InterCure | 0 | 0 | 0 | 0 | N/A |
Insider and Institutional Ownership
5.8% of Evotec shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Evotec has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.
Valuation & Earnings
This table compares Evotec and InterCure’s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Evotec | $791.73 million | 2.34 | -$185.07 million | N/A | N/A |
InterCure | $115.83 million | 1.05 | $13.36 million | $0.13 | 20.54 |
InterCure has lower revenue, but higher earnings than Evotec.
Summary
Evotec beats InterCure on 4 of the 7 factors compared between the two stocks.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
About InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.